The U.S. China Economic & Security Review Commission heard from witnesses about keeping auto tariffs on China, and more incentives for manufacturing to reshore.
Background De minimis is a regulatory loophole. It was morphed from a tiny customs administrative exception into a backdoor superhighway through our ports. The regulatory
In latest House Select Committee on the CCP, outbound investment restrictions get favorable view.
Trump’s call to reshore pharmaceutical production, especially critical medicine in short supply, will set the table for other presidential candidates. Reshoring America’s medicine supply chain is increasingly mainstream, and an easy sell to voters.
A Chinese cancer drug maker that has not been inspected by the FDA since 2018 is selling chemotherapy drugs to the U.S. due to shortages. When will the U.S. meet its critical medication needs?
The balance between scarcity and supply favors supply, even if that means importing drugs from labs the FDA has not inspected.
At a recent House Ways & Means subcommittee hearing on trade, CEO Michael Stumo talks de minimis, and the inescapable realities of China’s forced labor.
The following written testimony was submitted by Michael Stumo, CEO of CPA, to the House Ways and Means Subcommittee on Trade for a hearing titled,
The U.S. is increasingly reliant on imported drugs from uninspected labs. It’s not safe. What can be done about it?
The following written testimony was submitted to the Congressional-Executive Commission China (CECC) on April 18, 2023 by CPA’s Robby Stephany Saunders, Vice President for National
